Search

Ocrevus (ocrelizumab) is the first and only licensed treatment for people with early, inflammatory primary progressive multiple sclerosis in Ireland.

Dublin, 1st of October 2020 – Roche Products (Ireland) Ltd. (“Roche”), today, announced that OCREVUS® (ocrelizumab) is now publicly available in Ireland to treat people living with primary progressive multiple sclerosis (PPMS). More than 9,000 people in Ireland are living with MS(1) and it is estimated that PPMS, a highly disabling form of MS, and according to MS Ireland, affects approximately 15% of people diagnosed with MS(1).

Deputy Chairperson

Today, October 6th marks the first ever European Carers Day. Mary Devereux shares her thoughts on why carers need more care.

The National Transport Authority are interested in hearing the views and concerns of people across Ireland in relation to accessibility of public transport in their area. They have created a survey which they have asked us to share with you. 

World Mental Health Day is marked on Saturday, 10th October 2020. MS and depression can be a very challenging experience, today Joan Jordan shares her story.

Registration for the EMSP's Annual Conference on the 19th and 20th of November is now officially open!

On October 19th, the Government announced that “support bubbles’ form part of their plan for tightening restrictions in response to rising cases of COVID-19. Support bubbles allow interaction between two households under conditions, for the duration of the Level 5 restrictions. You can only form a support bubble with one other household if they are not already part of one. This will essentially allow two households to act as one.

Are you currently accessing any supports and services online for your Neurological condition? 

This week Rosie Farrell shares her experience of what it means to have fatigue and how she deals with it.

Multiple Sclerosis International Federation global advice has just been updated. Find out about risk factors, prevention measures & advice on using different disease modifying therapies during the pandemic